BR0115580A - Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2 - Google Patents

Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2

Info

Publication number
BR0115580A
BR0115580A BR0115580-6A BR0115580A BR0115580A BR 0115580 A BR0115580 A BR 0115580A BR 0115580 A BR0115580 A BR 0115580A BR 0115580 A BR0115580 A BR 0115580A
Authority
BR
Brazil
Prior art keywords
receptor agonists
derivatives
aroylindole
compounds
aroilindol
Prior art date
Application number
BR0115580-6A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Carole Guillaumont
Murielle Rinaldi
Fabienne Vasse
Claude Vernhet
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR0115580A publication Critical patent/BR0115580A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)

Abstract

"DERIVADOS DE 3-AROILINDOL E A UTILIZAçãO DOS MESMOS COMO AGONISTAS DOS RECEPTORES CB2". Derivados de 3-aroilindol e a utilização dos mesmos como agonistas dos receptores CB~ 2~. A presente invenção refere-se aos compostos de fórmula: (I) assim como a respectiva preparação e as composições farmacêuticas que os contêm. Esses compostos são agonistas dos receptores aos canabinóides CB~ 2~.
BR0115580-6A 2000-11-22 2001-11-21 Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2 BR0115580A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0015158A FR2816938B1 (fr) 2000-11-22 2000-11-22 Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
PCT/FR2001/003665 WO2002042269A1 (fr) 2000-11-22 2001-11-21 Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2

Publications (1)

Publication Number Publication Date
BR0115580A true BR0115580A (pt) 2003-09-09

Family

ID=8856819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115580-6A BR0115580A (pt) 2000-11-22 2001-11-21 Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2

Country Status (32)

Country Link
US (1) US6995184B2 (pt)
EP (1) EP1339679B1 (pt)
JP (1) JP4264258B2 (pt)
KR (1) KR20030048161A (pt)
CN (1) CN1234688C (pt)
AR (1) AR033594A1 (pt)
AT (1) ATE301638T1 (pt)
AU (1) AU2002222001A1 (pt)
BG (1) BG107827A (pt)
BR (1) BR0115580A (pt)
CA (1) CA2427444A1 (pt)
CZ (1) CZ20031392A3 (pt)
DE (1) DE60112607T2 (pt)
DK (1) DK1339679T3 (pt)
DZ (1) DZ3443A1 (pt)
EA (1) EA005854B1 (pt)
EE (1) EE200300244A (pt)
ES (1) ES2247201T3 (pt)
FR (1) FR2816938B1 (pt)
HR (1) HRP20030417A2 (pt)
HU (1) HUP0400561A2 (pt)
IL (1) IL155634A0 (pt)
IS (1) IS6802A (pt)
MA (1) MA26959A1 (pt)
MX (1) MXPA03004549A (pt)
NO (1) NO20031952L (pt)
NZ (1) NZ525609A (pt)
PL (1) PL362276A1 (pt)
SK (1) SK6042003A3 (pt)
TW (1) TWI224592B (pt)
WO (1) WO2002042269A1 (pt)
ZA (1) ZA200303728B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2004103410A1 (en) 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
FR2847899B1 (fr) * 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2856684B1 (fr) 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
WO2005123053A2 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington’s disease
JP2008505965A (ja) 2004-07-12 2008-02-28 カディラ ヘルスケア リミティド カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007006102A (es) * 2004-11-22 2007-07-11 Threshold Pharmaceuticals Inc Agentes anti-cancer de union a tubulina y profarmacos de los mismos.
US7560481B2 (en) * 2004-12-21 2009-07-14 Abbott Laboratories Indoles are cannabinoid receptor ligands
FR2893615B1 (fr) * 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
RU2306906C1 (ru) * 2006-04-21 2007-09-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по здравоохранению и социальному развитию" Способ повышения зрительных функций при сублюксации хрусталика в случаях нарушения обмена в системе соединительной ткани
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
JP2009538933A (ja) * 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての化合物およびその使用
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
CA2681586A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
EP2160393A1 (en) 2007-05-18 2010-03-10 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2933697B1 (fr) * 2008-07-11 2010-08-13 Sanofi Aventis Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2334646A2 (en) * 2008-09-16 2011-06-22 Abbott Laboratories Substituted benzamides as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945533B1 (fr) 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
FR2950055A1 (fr) 2009-09-17 2011-03-18 Sanofi Aventis Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique
US20130178453A1 (en) * 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CN105899948A (zh) * 2013-11-28 2016-08-24 联邦科学技术研究组织 检测疟原虫感染的方法
CN108794379A (zh) * 2017-04-26 2018-11-13 华东师范大学 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
DE60030303T2 (de) * 1999-10-18 2007-10-11 The University Of Connecticut, Farmington Cannabimimetische indolderivate

Also Published As

Publication number Publication date
FR2816938A1 (fr) 2002-05-24
EA005854B1 (ru) 2005-06-30
BG107827A (bg) 2004-01-30
CN1483023A (zh) 2004-03-17
IS6802A (is) 2003-04-30
EA200300453A1 (ru) 2003-10-30
JP2004514668A (ja) 2004-05-20
DE60112607D1 (de) 2005-09-15
MA26959A1 (fr) 2004-12-20
NZ525609A (en) 2004-11-26
PL362276A1 (en) 2004-10-18
EP1339679B1 (fr) 2005-08-10
US6995184B2 (en) 2006-02-07
ATE301638T1 (de) 2005-08-15
KR20030048161A (ko) 2003-06-18
EE200300244A (et) 2003-10-15
HUP0400561A2 (hu) 2004-07-28
DZ3443A1 (fr) 2002-05-30
FR2816938B1 (fr) 2003-01-03
SK6042003A3 (en) 2003-12-02
US20040034090A1 (en) 2004-02-19
WO2002042269A1 (fr) 2002-05-30
IL155634A0 (en) 2003-11-23
ES2247201T3 (es) 2006-03-01
DK1339679T3 (da) 2005-12-12
TWI224592B (en) 2004-12-01
CN1234688C (zh) 2006-01-04
NO20031952D0 (no) 2003-04-29
MXPA03004549A (es) 2004-03-26
ZA200303728B (en) 2004-05-14
AR033594A1 (es) 2003-12-26
HRP20030417A2 (en) 2003-08-31
NO20031952L (no) 2003-07-22
CZ20031392A3 (cs) 2003-09-17
AU2002222001A1 (en) 2002-06-03
CA2427444A1 (fr) 2002-05-30
EP1339679A1 (fr) 2003-09-03
DE60112607T2 (de) 2006-06-14
JP4264258B2 (ja) 2009-05-13

Similar Documents

Publication Publication Date Title
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
BR0309106A (pt) Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BR0108894A (pt) Composição farmacêutica, compostos e processo de preparação de compostos
BR0108871A (pt) Composto, processo de preparação de compostos, e, composição farmacêutica
BR0214455A (pt) Derivados benzotiazol
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
YU56995A (sh) Soli derivata indola
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
PT1254134E (pt) Derivados de 1,3-di-hidro-2h-indol-2-ona e sua utilizacao como ligandos para os receptores v1b ou v1b e v1a da arginina-vasopressina
ATE229330T1 (de) Verwendung von n-acylvanillinamid-derivaten als agonisten der peripheren cannabinoid-cb1- rezeptoren
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
BR0112521A (pt) Indolquinazolinonas
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
BR0113425A (pt) Aminoalquilbenzoil-benzofuranos ou benzotiófenos, processo de preparação dos mesmos e as composições que os contêm
BR0014808A (pt) Processos de preparação de um composto, e, compostos nitroaromáticos
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
BR9807988A (pt) Processo para a preparação de um composto, e, composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.